In the first part of the Immuno-Oncology Primer, we will provide an overview of anti-cancer vaccines and cytokines before delving into a discussion of immune checkpoint inhibitors.

“These successes have refocused attention back on to immunotherapeutic approaches for treating cancer; specifically, the discovery and clinical successes of immune checkpoint inhibitors have revolutionized cancer immunotherapy, and the cancer immunotherapy market is forecasted to have sales of >$93B in 2023, the majority of which may be attributed to immune checkpoint inhibitors…”

Click here to read the full White Paper